"This trial is pivotal for Perseon, as it marks the first in vivo trial of its kind for MicroThermX," said Brian A. Meltzer, Chief Medical Officer of Perseon. "The push for real world results reinforces our commitment to clinically relevant data and further shows how our Synchronous Wave Alignment Technology provides added efficiency for physicians in the field of energy ablation."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.